62 related articles for article (PubMed ID: 22644862)
1. The impact of AT1002 on the delivery of ritonavir in the presence of bioadhesive polymer, carrageenan.
Song KH; Eddington ND
Arch Pharm Res; 2012 May; 35(5):937-43. PubMed ID: 22644862
[TBL] [Abstract][Full Text] [Related]
2. The influence of stabilizer and bioadhesive polymer on the permeation-enhancing effect of AT1002 in the nasal delivery of a paracellular marker.
Song KH; Eddington ND
Arch Pharm Res; 2012 Feb; 35(2):359-66. PubMed ID: 22370791
[TBL] [Abstract][Full Text] [Related]
3. The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001.
Song KH; Eddington ND
J Pharm Pharmacol; 2012 Jan; 64(1):30-9. PubMed ID: 22150669
[TBL] [Abstract][Full Text] [Related]
4. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A.
Song KH; Fasano A; Eddington ND
Int J Pharm; 2008 Mar; 351(1-2):8-14. PubMed ID: 17954018
[TBL] [Abstract][Full Text] [Related]
5. Paracellular permeation-enhancing effect of AT1002 C-terminal amidation in nasal delivery.
Song KH; Kim SB; Shim CK; Chung SJ; Kim DD; Rhee SK; Choi GJ; Kim CH; Kim K
Drug Des Devel Ther; 2015; 9():1815-23. PubMed ID: 25848218
[TBL] [Abstract][Full Text] [Related]
6. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator.
Song KH; Fasano A; Eddington ND
Eur J Pharm Biopharm; 2008 May; 69(1):231-7. PubMed ID: 18039562
[TBL] [Abstract][Full Text] [Related]
7. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin.
Motlekar NA; Fasano A; Wachtel MS; Youan BB
J Drug Target; 2006 Jun; 14(5):321-9. PubMed ID: 16882552
[TBL] [Abstract][Full Text] [Related]
8. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
9. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharmacol Exp Ther; 2005 Jan; 312(1):199-205. PubMed ID: 15448170
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
Uchida T; Kanazawa T; Kawai M; Takashima Y; Okada H
J Pharmacol Exp Ther; 2011 Aug; 338(2):443-50. PubMed ID: 21531792
[TBL] [Abstract][Full Text] [Related]
11. Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-κB decoy oligodeoxynucleotide.
Fukuta T; Tanaka D; Inoue S; Michiue K; Kogure K
Int J Pharm; 2021 Jun; 602():120601. PubMed ID: 33905867
[TBL] [Abstract][Full Text] [Related]
12. Enhanced local anesthetic action of mepivacaine from the bioadhesive gels.
Cho CW; Choi JS; Shin SC
Pak J Pharm Sci; 2011 Jan; 24(1):87-93. PubMed ID: 21190925
[TBL] [Abstract][Full Text] [Related]
13. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
14. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies.
Bonferoni MC; Chetoni P; Giunchedi P; Rossi S; Ferrari F; Burgalassi S; Caramella C
Eur J Pharm Biopharm; 2004 May; 57(3):465-72. PubMed ID: 15093594
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies.
Charlton ST; Davis SS; Illum L
J Control Release; 2007 Apr; 118(2):225-34. PubMed ID: 17261340
[TBL] [Abstract][Full Text] [Related]
16. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
17. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
18. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.
Ved PM; Kim K
Int J Pharm; 2011 Jun; 411(1-2):1-9. PubMed ID: 21356294
[TBL] [Abstract][Full Text] [Related]
19. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract.
Lehr CM
Crit Rev Ther Drug Carrier Syst; 1994; 11(2-3):119-60. PubMed ID: 7600586
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
